Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
American Journal of Hematology|February 22, 2023
DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b studyScott F Huntington, Stephen J Schuster, Wei Ding, et al.
The Lancet. Haematology|August 30, 2016
Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trialPaolo Strati, Mark Lanasa, Timothy G Call, et al.
Haematologica|June 9, 2018
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United StatesAnthony R Mato, Meghan Thompson, John N Allan, et al.
Leukemia|January 30, 2023
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemiaChristine E Ryan, Danielle M Brander, Paul M Barr, et al.
The Lancet. Haematology|February 25, 2021
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trialJeff P Sharman, Danielle M Brander, Anthony R Mato, et al.
Haematologica|October 15, 2020
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaborationDeborah M Stephens, Ken Boucher, Elizabeth Kander, et al.
Leukemia|July 18, 2021
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202Amy S Ruppert, Allison M Booth, Wei Ding, et al.
Blood Advances|December 20, 2024
A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignanciesMatthew S Davids, Danielle M Brander, Yesid Alvarado-Valero, et al.
Lancet (London, England)|June 9, 2023
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 studyTanya Siddiqi, David G Maloney, Saad S Kenderian, et al.
Blood Advances|January 1, 2024
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLLInhye E Ahn, Danielle M Brander, Yue Ren, et al.
Pageof 6